
    
      -  This is a 3-year study and the enrollment time of this study is 24 months.

        -  The participants have to receive the investigational agent:Cerdelga.(Cerdelga have 21
           mgã€42 mg and 84 mg capsule.)

        -  The participants have to go back to the hospital and receive the investigational agent
           and take the Gaucher related biomarkers test before receiving Cerdelga, and 2 weeks, 1,
           3, 6, 12, 18 and 24 months after receiving Cerdelga.

        -  The participants have to inform if any adverse events happened.

        -  The investigators will follow up by phone if adverse events happened in the participants
           after one months start the treatment.
    
  